Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder

Journal of Clinical Psychiatry

Volumn 63, Issue 9, 2002, Pages 763-771

  Kane, John M ^a   Carson, William H ^a   Saha, Anutosh R ^a   McQuade, Robert D ^a   Ingenito, Gary G ^a   Zimbroff, Dan L ^a   Ali, Mirza W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; OLANZAPINE; PLACEBO; PROLACTIN; RISPERIDONE;

ABDOMINAL PAIN; ADULT; AGED; AKATHISIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; NAUSEA; NEGATIVE SYNDROME; ORTHOSTATIC HYPOTENSION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHIATRIC DIAGNOSIS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TREMOR; VERTIGO; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN;

EID: 0036738786     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0903     Document Type: Article

References (37)

1. Murray CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996;274:740-743
2. Bunney WE, Meltzer HY. Schizophrenia: overview. Clin Neurosci 1995;3:55-56
3. Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 1990;4:2737-2744
4. Anden N, Butcher SG, Corrodi H, et al. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 1970;11:303-314
5. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-483
6. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179-186
7. Emilien G, Maloteaux JM, Geurts M, et al. Dopamine receptors: physiological understanding to therapeutic intervention potential. Pharmacol Ther 1999;84:133-156
8. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60(suppl 10):5-14
9. Fleischhacker WW, Meise U, Gunther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 1994;382:11-15
10. Kurzthaler I, Fleishhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001;62(suppl 7):32-37
11. Lahti AC, Weiler MA, Corey PK, et al. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiatry 1998;43:2-11
12. Sramek JJ, Eldon MA, Posvar EL, et al. Initial safety, tolerability, pharmacodynamics and pharmacokinetics of CI-1007 in patients with schizophrenia. Psychopharmacol Bull 1998;34:93-99
13. Iyer RN, Davis MD, Juneau PL, et al. Brain extracellular levels of the putative antipsychotic CI-1007 and its effects on striatal and nucleus accumbens dopamine overflow in the awake rat. J Pharm Pharmacol 1998;50:1147-1153
14. 2 receptors. J Pharmacol Exp Ther 2002;302:381-389
15. 1A receptor. Eur J Pharmacol 2002;441:137-140
16. McQuade RD, Burris KD, Jordan S, et al. Aripiprazole: a dopamineserotonin system stabilizer. Int J Neuropsychopharmacol 2002(June); 5(suppl 1):S176
17. Carlsson A, Waters N, Waters S, et al. Network interactions in schizophrenia: therapeutic implications. Brain Res Rev 2000;31:342-349
18. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, pt 1: "Goldilocks" actions at dopamine receptors [BRAINSTORMS]. J Clin Psychiatry 2001;62:841-842
19. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, pt 2: Illustrating their mechanism of action [BRAINSTORMS]. J Clin Psychiatry 2001;62:923-924
20. 2 receptor antagonist activity. J Pharmacol Exp Ther 1995;274:329-336
21. Inoue T, Domae M, Yamada K, et al. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H) -quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996;277:137-143
22. Glennon RA, Dukat M. Serotonin receptor subtypes. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:419
23. Jann MW. Buspirone: an update on a unique anxiolytic agent. Pharmacotherapy 1988;8:100-116
24. Sovner R, Parnell-Sovner N. Use of buspirone in the treatment of schizophrenia. J Clin Psychopharmacol 1989;9:61-62
25. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 2000;295:853-861
26. 2 receptors. Psychopharmacology 1993;112:S40
27. Rao ML, Muller HJ. Biochemical findings of negative symptoms in schizophrenia and their positive relevance to pharmacologic treatment. Neuropsychobiology 1994;30:160-164
28. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
29. Clinical Global Impressions (CGI). In: Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
30. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;45(suppl 212):11-19
31. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
32. Abnormal Involuntary Movement Scale (AIMS). In: Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-537
33. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(suppl 7):22-31
34. Gury C, Canceil O, Iaria P. Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale 2000;26:62-72
35. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999;35:S75-S86
36. Carson WH, McQuade RD, Ali M, et al. A double-blind, placebo-controlled trial of aripiprazole and haloperidol. Schizophr Res 2001;49 (suppl 1):221
37. Daniel DG, Saha AR, Ingenito G, et al. Aripiprazole, a novel antipsychotic: overview of a phase II study result. Int J Neuropsychopharmacol 2000;3(suppl 1):S157